Taysha Gene Therapies taps Catalent for TSHA-102 Rett syndrome commercial manufacturing support
TSHA•Commercialization readiness work underway
Taysha noted BLA-enabling process performance qualification work is underway to support commercialization readiness.
Commercial supply agreement signed for TSHA-102
Taysha Gene Therapies signed a commercial supply agreement with Catalent for TSHA-102, its gene therapy in pivotal development for Rett syndrome.
Catalent is set to become the primary commercial manufacturer if the FDA approves TSHA-102, securing long-term capacity for a potential U.S. launch.
Manufacturing would run at Catalent’s FDA-licensed gene therapy facility in Harmans, Maryland, extending a development partnership in place since 2020.
